Trial
NCT01090414
An Extension Study for Subjects Who Are Deriving Benefit With Idelalisib (GS-1101; CAL-101) Following Completion of a Prior Idelalisib Study
Phase ITERMINATEDSAFETYConfidence: HIGH
Sponsor
Gilead Sciences
Collaborators
—
Condition
Chronic Lymphocytic Leukemia
Intervention
Idelalisib
Why stopped
—
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-08-28